S&P 500   3,638.35 (+0.24%)
DOW   29,910.37 (+0.13%)
QQQ   299.19 (+0.98%)
AAPL   116.45 (+0.36%)
MSFT   215.19 (+0.62%)
FB   277.60 (+0.73%)
GOOGL   1,785.94 (+1.24%)
AMZN   3,196.00 (+0.34%)
TSLA   585.16 (+1.94%)
NVDA   530.10 (+0.13%)
BABA   276.50 (-0.44%)
CGC   29.00 (+7.93%)
GE   10.40 (-0.95%)
MU   64.07 (+1.01%)
AMD   87.17 (+0.53%)
T   29.03 (+0.14%)
NIO   53.88 (+0.35%)
F   9.10 (+0.22%)
ACB   10.55 (+21.13%)
NFLX   491.36 (+1.31%)
BA   216.66 (-0.44%)
GILD   59.99 (+0.82%)
DIS   147.01 (-1.40%)
S&P 500   3,638.35 (+0.24%)
DOW   29,910.37 (+0.13%)
QQQ   299.19 (+0.98%)
AAPL   116.45 (+0.36%)
MSFT   215.19 (+0.62%)
FB   277.60 (+0.73%)
GOOGL   1,785.94 (+1.24%)
AMZN   3,196.00 (+0.34%)
TSLA   585.16 (+1.94%)
NVDA   530.10 (+0.13%)
BABA   276.50 (-0.44%)
CGC   29.00 (+7.93%)
GE   10.40 (-0.95%)
MU   64.07 (+1.01%)
AMD   87.17 (+0.53%)
T   29.03 (+0.14%)
NIO   53.88 (+0.35%)
F   9.10 (+0.22%)
ACB   10.55 (+21.13%)
NFLX   491.36 (+1.31%)
BA   216.66 (-0.44%)
GILD   59.99 (+0.82%)
DIS   147.01 (-1.40%)
S&P 500   3,638.35 (+0.24%)
DOW   29,910.37 (+0.13%)
QQQ   299.19 (+0.98%)
AAPL   116.45 (+0.36%)
MSFT   215.19 (+0.62%)
FB   277.60 (+0.73%)
GOOGL   1,785.94 (+1.24%)
AMZN   3,196.00 (+0.34%)
TSLA   585.16 (+1.94%)
NVDA   530.10 (+0.13%)
BABA   276.50 (-0.44%)
CGC   29.00 (+7.93%)
GE   10.40 (-0.95%)
MU   64.07 (+1.01%)
AMD   87.17 (+0.53%)
T   29.03 (+0.14%)
NIO   53.88 (+0.35%)
F   9.10 (+0.22%)
ACB   10.55 (+21.13%)
NFLX   491.36 (+1.31%)
BA   216.66 (-0.44%)
GILD   59.99 (+0.82%)
DIS   147.01 (-1.40%)
S&P 500   3,638.35 (+0.24%)
DOW   29,910.37 (+0.13%)
QQQ   299.19 (+0.98%)
AAPL   116.45 (+0.36%)
MSFT   215.19 (+0.62%)
FB   277.60 (+0.73%)
GOOGL   1,785.94 (+1.24%)
AMZN   3,196.00 (+0.34%)
TSLA   585.16 (+1.94%)
NVDA   530.10 (+0.13%)
BABA   276.50 (-0.44%)
CGC   29.00 (+7.93%)
GE   10.40 (-0.95%)
MU   64.07 (+1.01%)
AMD   87.17 (+0.53%)
T   29.03 (+0.14%)
NIO   53.88 (+0.35%)
F   9.10 (+0.22%)
ACB   10.55 (+21.13%)
NFLX   491.36 (+1.31%)
BA   216.66 (-0.44%)
GILD   59.99 (+0.82%)
DIS   147.01 (-1.40%)
Log in
OTCMKTS:CVAT

Cavitation Technologies Competitors

$0.02
-0.01 (-40.00 %)
(As of 11/25/2020 12:00 AM ET)
Add
Compare
Today's Range
$0.02
Now: $0.02
$0.02
50-Day Range
$0.01
MA: $0.01
$0.02
52-Week Range
$0.01
Now: $0.02
$0.05
VolumeN/A
Average Volume226,431 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Cavitation Technologies (OTCMKTS:CVAT) Vs. NTR, SMG, MOS, CF, ICL, and AVD

Should you be buying CVAT stock or one of its competitors? Companies in the industry of "agricultural chemicals" are considered alternatives and competitors to Cavitation Technologies, including Nutrien (NTR), The Scotts Miracle-Gro (SMG), The Mosaic (MOS), CF Industries (CF), ICL Group (ICL), and American Vanguard (AVD).

Cavitation Technologies (OTCMKTS:CVAT) and Nutrien (NYSE:NTR) are both basic materials companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, valuation, institutional ownership, analyst recommendations, risk and dividends.

Analyst Recommendations

This is a summary of current recommendations and price targets for Cavitation Technologies and Nutrien, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cavitation Technologies0000N/A
Nutrien071212.70

Nutrien has a consensus price target of $46.4706, indicating a potential downside of 5.95%. Given Nutrien's higher probable upside, analysts clearly believe Nutrien is more favorable than Cavitation Technologies.

Earnings & Valuation

This table compares Cavitation Technologies and Nutrien's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cavitation TechnologiesN/AN/AN/AN/AN/A
Nutrien$20.02 billion1.40$992 million$2.1722.77

Nutrien has higher revenue and earnings than Cavitation Technologies.

Profitability

This table compares Cavitation Technologies and Nutrien's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cavitation TechnologiesN/AN/AN/A
Nutrien0.47%4.19%1.98%

Insider and Institutional Ownership

63.2% of Nutrien shares are owned by institutional investors. 3.1% of Nutrien shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Nutrien beats Cavitation Technologies on 9 of the 9 factors compared between the two stocks.

Cavitation Technologies (OTCMKTS:CVAT) and The Scotts Miracle-Gro (NYSE:SMG) are both basic materials companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, valuation, institutional ownership, analyst recommendations, risk and dividends.

Analyst Recommendations

This is a summary of current recommendations and price targets for Cavitation Technologies and The Scotts Miracle-Gro, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cavitation Technologies0000N/A
The Scotts Miracle-Gro02302.60

The Scotts Miracle-Gro has a consensus price target of $161.75, indicating a potential downside of 5.84%. Given The Scotts Miracle-Gro's higher probable upside, analysts clearly believe The Scotts Miracle-Gro is more favorable than Cavitation Technologies.

Earnings & Valuation

This table compares Cavitation Technologies and The Scotts Miracle-Gro's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cavitation TechnologiesN/AN/AN/AN/AN/A
The Scotts Miracle-Gro$3.16 billion3.04$460.70 million$4.4738.43

The Scotts Miracle-Gro has higher revenue and earnings than Cavitation Technologies.

Profitability

This table compares Cavitation Technologies and The Scotts Miracle-Gro's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cavitation TechnologiesN/AN/AN/A
The Scotts Miracle-Gro8.71%45.36%9.86%

Insider and Institutional Ownership

64.9% of The Scotts Miracle-Gro shares are owned by institutional investors. 28.2% of The Scotts Miracle-Gro shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

The Scotts Miracle-Gro beats Cavitation Technologies on 8 of the 8 factors compared between the two stocks.

Cavitation Technologies (OTCMKTS:CVAT) and The Mosaic (NYSE:MOS) are both basic materials companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, valuation, institutional ownership, analyst recommendations, risk and dividends.

Insider and Institutional Ownership

71.6% of The Mosaic shares are owned by institutional investors. 0.5% of The Mosaic shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Cavitation Technologies and The Mosaic's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cavitation TechnologiesN/AN/AN/AN/AN/A
The Mosaic$8.91 billion0.97$-1,067,400,000.00$0.19119.42

Cavitation Technologies has higher earnings, but lower revenue than The Mosaic.

Analyst Recommendations

This is a summary of current recommendations and price targets for Cavitation Technologies and The Mosaic, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cavitation Technologies0000N/A
The Mosaic111802.35

The Mosaic has a consensus price target of $18.2368, indicating a potential downside of 19.63%. Given The Mosaic's higher probable upside, analysts clearly believe The Mosaic is more favorable than Cavitation Technologies.

Profitability

This table compares Cavitation Technologies and The Mosaic's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cavitation TechnologiesN/AN/AN/A
The Mosaic-13.05%N/AN/A

Summary

The Mosaic beats Cavitation Technologies on 5 of the 6 factors compared between the two stocks.

CF Industries (NYSE:CF) and Cavitation Technologies (OTCMKTS:CVAT) are both basic materials companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, earnings, profitability, analyst recommendations and risk.

Insider and Institutional Ownership

88.9% of CF Industries shares are owned by institutional investors. 2.0% of CF Industries shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares CF Industries and Cavitation Technologies' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CF Industries$4.59 billion1.81$493 million$1.9320.11
Cavitation TechnologiesN/AN/AN/AN/AN/A

CF Industries has higher revenue and earnings than Cavitation Technologies.

Analyst Ratings

This is a breakdown of recent ratings and target prices for CF Industries and Cavitation Technologies, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CF Industries17802.44
Cavitation Technologies0000N/A

CF Industries presently has a consensus target price of $38.0769, indicating a potential downside of 1.89%. Given CF Industries' higher possible upside, research analysts plainly believe CF Industries is more favorable than Cavitation Technologies.

Profitability

This table compares CF Industries and Cavitation Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CF Industries7.00%5.14%2.34%
Cavitation TechnologiesN/AN/AN/A

Summary

CF Industries beats Cavitation Technologies on 8 of the 8 factors compared between the two stocks.

ICL Group (NYSE:ICL) and Cavitation Technologies (OTCMKTS:CVAT) are both basic materials companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, earnings, profitability, analyst recommendations and risk.

Insider and Institutional Ownership

4.3% of ICL Group shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares ICL Group and Cavitation Technologies' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ICL Group$5.27 billion1.16$475 million$0.3712.89
Cavitation TechnologiesN/AN/AN/AN/AN/A

ICL Group has higher revenue and earnings than Cavitation Technologies.

Analyst Ratings

This is a breakdown of recent ratings and target prices for ICL Group and Cavitation Technologies, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ICL Group02002.00
Cavitation Technologies0000N/A

ICL Group presently has a consensus target price of $5.50, indicating a potential upside of 15.30%. Given ICL Group's higher possible upside, research analysts plainly believe ICL Group is more favorable than Cavitation Technologies.

Profitability

This table compares ICL Group and Cavitation Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ICL Group1.41%7.76%3.35%
Cavitation TechnologiesN/AN/AN/A

Summary

ICL Group beats Cavitation Technologies on 6 of the 6 factors compared between the two stocks.

American Vanguard (NYSE:AVD) and Cavitation Technologies (OTCMKTS:CVAT) are both basic materials companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, earnings, profitability, analyst recommendations and risk.

Insider and Institutional Ownership

63.6% of American Vanguard shares are owned by institutional investors. 5.3% of American Vanguard shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares American Vanguard and Cavitation Technologies' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
American Vanguard$468.19 million1.00$13.60 million$0.4633.72
Cavitation TechnologiesN/AN/AN/AN/AN/A

American Vanguard has higher revenue and earnings than Cavitation Technologies.

Analyst Ratings

This is a breakdown of recent ratings and target prices for American Vanguard and Cavitation Technologies, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
American Vanguard0000N/A
Cavitation Technologies0000N/A

Profitability

This table compares American Vanguard and Cavitation Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
American Vanguard2.40%3.16%1.61%
Cavitation TechnologiesN/AN/AN/A

Summary

American Vanguard beats Cavitation Technologies on 6 of the 6 factors compared between the two stocks.


Cavitation Technologies Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Nutrien logo
NTR
Nutrien
1.5$49.41-1.7%$27.65 billion$20.02 billion290.65Analyst Revision
The Scotts Miracle-Gro logo
SMG
The Scotts Miracle-Gro
1.6$171.79-1.4%$9.45 billion$3.16 billion30.14
The Mosaic logo
MOS
The Mosaic
1.9$22.69-0.5%$8.56 billion$8.91 billion-7.91Analyst Downgrade
CF Industries logo
CF
CF Industries
1.9$38.81-1.6%$8.27 billion$4.59 billion29.40
ICL Group logo
ICL
ICL Group
1.7$4.77-1.3%$6.03 billion$5.27 billion79.50
American Vanguard logo
AVD
American Vanguard
0.6$15.51-0.1%$475.52 million$468.19 million41.92
Marrone Bio Innovations logo
MBII
Marrone Bio Innovations
1.3$1.17-0.9%$176.87 million$29.37 million-4.03
Calyxt logo
CLXT
Calyxt
1.4$3.88-0.3%$141.96 million$7.30 million-2.92
CVR Partners logo
UAN
CVR Partners
1.5$9.00-0.1%$99.78 million$404.18 million-9.28Analyst Downgrade
Evogene logo
EVGN
Evogene
0.5$2.93-1.0%$74.68 million$750,000.00-3.66
CGA
China Green Agriculture
0.8$2.77-0.4%$17.56 million$294.32 million0.00Upcoming Earnings
BNET
Bion Environmental Technologies
0.6$0.51-2.0%$16.03 millionN/A0.00High Trading Volume
SenesTech logo
SNES
SenesTech
0.8$1.67-6.2%$6.42 million$140,000.00-0.22
KWBT
Kiwa Bio-Tech Products Group
0.6$0.00-0.0%$1.82 million$40.09 million-0.01Upcoming Earnings
This page was last updated on 11/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.